TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication.
Daniel Wai-Hung HoLo K ChanYung T ChiuIris M J XuRonnie T P PoonTan T CheungChung N TangVictor W L TangIrene L O LoPolly W Y LamDerek T W YauMiao X LiChun M WongIrene O L NgPublished in: Gut (2016)
Taken together, our findings suggest the significance of previously undocumented mutation-dependent mTOR hyperactivation and frequent TSC1/2 mutations in HBV-associated HCCs. They define a molecular subset of HCC having genetic aberrations in mTOR signalling, with potential significance of effective specific drug therapy.